Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- The 53 most innovative companies in healthcare (Advisory Board)
- Delaying DOAC after colonoscopy: Weighing the risks (MDedge)
- Practice-changing takeaways from the 2026 Gut Microbiota Summit: A clinical reality check (MDLinx)
- ‘Phenomenal’ Tech May Boost Adenoma Detection in Colonoscopy (Medscape)
- CEO of America’s largest public hospital system says he’s ready to replace radiologists with AI (Radiology Business)
- OpenEvidence and Tandem Partner to Streamline Evidence-Based Prescribing and Prior Authorizations (Business Wire)
- Where GI training may fall short (Becker’s GI & Endoscopy)
- AI gut health startups are selling answers that science can’t back up (PitchBook)
